European Journal of Vascular & Endovascular Surgery
Volume 25, Issue 1 , Pages 6-15 , January 2003

The role of platelets in peripheral vascular disease

,Accepted 5 October 2002.

References 

  1. Antithrombotic Trialists' Group . Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  2. Antiplatelet Trialists' Collaboration . Collaborative Overview of randomised trials of antiplatelet therapy–II: Maintenance of Vascular Graft or arterial patency by antiplatelet therapy. BMJ. 1994;308:159–168
  3. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell. Science. 1973;180:1332–1339
  4. Ross R, Glomset JA. The pathogenesis of atherosclerosis (Part I). NEJM. 1976;295:369–375
  5. Ross R, Glomset JA. The pathogenesis of atherosclerosis (Part II). NEJM. 1976;295:420–425
  6. D'Souza D, Wu KK, Hellums JD, Phillips MD. Platelet activation and arterial thrombosis. Lancet. 1994;334:991–995
  7. Nakamura T, Kambayashi J, Okuma M, Tandon NN. Activation of the GPIIb/IIIa complex induced by platelet adhesion to collagen is mediated by both alpha2-beta1 integrin and GPVI. J Biol Chem. 1999;274:11897–11903
  8. Zaffran Y, Meyer SC, Negrescu E, Reddy KB, Fox JE. Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha IIb beta 3 activation both in platelets and a transfected Chinese hamster ovary cell system. J Biol Chem. 2000;275:16779–16787
  9. Shattil SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in and sideways. Thromb Haemost. 1999;82:318–325
  10. Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature. 1961;192:531–533
  11. Gaarder A, Laland S. Hypothesis for the aggregation of platelets by nucleotides. Nature. 1964;292:909–911
  12. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Throm Basic Biol. 1999;19:2281–2285
  13. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate induced thromboxane A2 generation in human platelets requires coordinated signaling through integrin alpha IIb beta 3 and ADP receptors. Blood. 2002;99:193–198
  14. McEver RP, Beckstead JH, Moore KL, Marshall-Carison L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest. 1989;84:92–99
  15. Lorant DE, Topham MK, Whatley RE, et al.  Inflammatory roles of P-selectin. J Clin Invest. 1993;92:559–570
  16. McEver RP. Selectins: novel receptors that mediate leukocyte adhesion during inflammation. Thromb Haemost. 1991;65:223–228
  17. Palabrica T, Lobb R, Furie Bc, et al.  Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359:848–851
  18. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis. 1984;4:323–340
  19. Fitzgerald DJ. Vascular biology of thrombosis: the role of platelet-vessel wall adhesion. Neurology. 2001;57:S1–S4
  20. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407:258–264
  21. Ross R. The pathogenesis of atherosclerosis: an update. NEJM. 1986;314:488–499
  22. Tennant M, McGeachie JK, Dilley RJ, Prendergast FJ. Histogenesis of arterial intimal hyperplasia and atherosclerosis. Aust NZJ Surg. 1990;69:79–85
  23. Heldin CG, Wasterson A, Westermark B. Platelet-derived growth factor. Mol Cell Endocrinol. 1985;39:169–187
  24. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Plateletderived growth factor mRNA detection in human artherosclerotic plaques by in situ hybridization. J Clin Invest. 1988;82:1134–1143
  25. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Inv. 1992;89:507–511
  26. Gordon D, Schwartz SM, Benditt EP, Wilcox JN. Growth factors and cell proliferation in human artherosclerosis. Transplanation Proc. 1989;21:3692–3694
  27. Stemerman MB, Ross R. Experimental arteriosclerosis. I. Fibrous plaque formation in primates, an electron microscope study. J Exp Med. 1972;136:769–789
  28. Di Minno G, Davi G, Margaglione M, et al.  Abnormally high thromboxane biosynthesis in homozygous homocystinuria–evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92:1400–1406
  29. Friedman RJ, Stemerman MB, Wenz B, et al.  The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J C Invest. 1977;60:1191–1201
  30. Banga JD, Sixma JJ. Diabetes mellitus, vascular disease and thrombosis. Clin Haematol. 1986;15:564–592
  31. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Proc Cardiovasc Dis. 1984;26:373–412
  32. Hendra T, Betteridge DJ. Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids. 1989;35:197–212
  33. Winocour PD. Platelet abnormalities in Diabetes Mellitus. Diabetes. 1992;41:26–31
  34. Guillausseau PJ, Dupuy E, Bryckaert MC, et al.  Platelet derived growth factor in type I diabetes mellitus. Eur J Clin Invest. 1989;19:172–175
  35. Packham MA, Mustard JF. Platelet aggregation: relevance to thrombotic tendencies. Adv Exp Med Biol. 1978;102:51–72
  36. Lee M, Paton RC, Passa P, Caen JP. Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects. Thromb Res. 1981;24:143–150
  37. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998;94:657–666
  38. De Marco L, Girolami A, Russell S, Ruggeri SM. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest. 1985;75:1198–1203
  39. Fernandez-Ortiz A, Badimon JJ, Falk E, et al.  Characterisation of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562–1569
  40. Toschi V, Gallo R, Lettino M, et al.  Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594–599
  41. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localisation of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839–2843
  42. Schoop W, Levy H. Prevention of peripheral arterial occlusive disease with antiaggregants. Thromb Haemost. 1983;50:137
  43. Nordestgaard AG, Marcus CS, Wilson SE. Effect of aspirin and dipyridamole on sequential graft platelet accumulation after implantation of small diameter PTFE prosthesis. Platelets. 1990;1:37–41
  44. Eldrup-Jorgensen J, Mackey WC, Connolly RJ, et al.  Evaluation of arterial prosthese in a baboon ex vivo shunt: the effect of graft material and flow on platelet deposition. Am J Surg. 1985;150:185–190
  45. Hanson SR, Kotze HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis. 1985;5:595–603
  46. Allen BT, Mathias CJ, Sicard GA, Welch MJ, Clark RE. Platelet deposition on vascular grafts. The accuracy of in vivo quantitation and the significance of in vivo platelet reactivity. Ann Surg. 1986;203:318–328
  47. Eldrup-Jorgensen J, Connolly RJ, Mackey WC, et al.  Antiplatelet therapy and vascular grafts. Studies in a baboon ex vivo shunt. Arch Surg. 1986;121:778–781
  48. Rumisek JD, Wade CE, Kaplan K, et al.  The influence of early surface thromboreactivity on long-term arterial graft patency. Surgery. 1989;105:654–661
  49. Goldman M, Norcott HC, Hawker RJ, Drolc Z, McCollum CN. Platelet accumulation on mature Dacron grafts in man. Br J Surg. 1982;69:S38–S40
  50. Goldman M, Norcott HC, Hawker RJ, Hail C, Drole Z, McCollum CN. Femoropopliteal bypass grafts–an isotope technique allowing in vivo comparison of thrombogenicity. Br J Surg. 1982;69:380–382
  51. Brewster DC, LaSalle AJ, Robison JG, Strayhorn EC, Darling RC. Factors affecting patency of femoropopliteal bypass grafts. Surg Gyn & Obst. 1983;157:437–442
  52. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-dependent relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987;92:181–187
  53. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregatory properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639–646
  54. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057–1058
  55. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension. 1988;12:530–548
  56. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis. 1991;34:45–68
  57. Dilley RJ, McGeachie JK, Tennant M. Vein to artery grafts: a morphological and histochemical study of the histogenesis of intimal hyperplasia. Aust N Z J Surg. 1992;62:297–303
  58. Goldman M, Simpson D, Hawker RJ, Norcott HC, McCollum CN. Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg. 1983;198:713–716
  59. Goldman M, Hall C, Dykes J, Hawker RJ, McCollum CN. Does 111indium-platelet deposition predict patency in prosthetic arterial grafts?. Br J Surg. 1983;70:635–638
  60. Dutch Bypass Oral Anticoagulants or Aspirin BOA Study Group . Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet. 2000;355:346–351
  61. Green RM, Roedersheimer LR, DeWeese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery. 1982;92:1016–1026
  62. Sheehan SJ, Salter MCP, Donaldson DR, Rajah SM, Kester RC. Five year follow up of long-term aspirin/dipyridamole in femoropopliteal Dacron bypass grafts. Br J Surg. 1987;74:330
  63. Becquemin JP. Effect of Ticlopidine on the longterm patency of saphenous-vein bypass grafts in the legs. NEJM. 1997;337:1726–1731
  64. Rutherford RB, Jones DN, Bergentz SE, et al.  The efficacy of dextran 40 in preventing early postoperative thrombosis following difficult lower extremity bypass. J Vasc Surg. 1984;1:765–773
  65. Shoenfeld NA, Eldrup-Jorgensen J, Connolly R, et al.  The effect of low molecular weight dextran on platelet deposition onto prosthetic materials. J Vasc Surg. 1987;5:76–82
  66. Batlle J, del Rio F, Lopez Fernandez MF, Martin R, Lopez Borrasca A. Effect of dextran on factor VIII/von Willebrand factor structure and function. Thromb Haemost. 1985;54:697–699
  67. Nazzal W, Owunwanne A, Christenson JT. Direct platelet effect of low molecular weight dextran in small caliber PTFE grafts. Eur J Vasc Surg. 1991;5:169–172
  68. Whittemore AD, Clowes AW, Couch NP, Mannick JA. Secondary femoropopliteal reconstruction. Ann Surg. 1981;193:35–42
  69. Kagan SA, Myers SI. Mediators of restenosis. Surg Cl N America. 1998;78:481–500
  70. Nakamura H, Ohtsuba KI. Ultrastructural appearance of atherosclerosis in human and experimentally induced animal models. Electron Microsc Rev. 1992;5:129
  71. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997;204:87–96
  72. Karch LA, Mattos MA, Henretta JP, McLafferty RB, Ramsey DE, Hodgson KJ. Clinical failure after percutaneous transluminal angioplasty of the superficial femoral and popliteal arteries. J Vasc Surg. 2000;31:880–887
  73. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol. 1987;60:20–28
  74. Losordo DW, Rosenfield K, Pieczek A, Baker K, Harding M, Isner JM. How does angioplasty work? Serial analysis of human iliac arteries using intravascular ultrasound. Circulation. 1992;86:1845–1858
  75. Lyon RT, Zarins CK, Lu C-T, Yang C-F, Glagov S. Vessel, plaque, and lumen morphology after transluminal balloon angioplasty: quantitative study in distended human arteries. Arteriosclerosis. 1987;7:306–314
  76. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation. 1987;75:636–642
  77. Poskitt KR, Harwood A, Scott DJ, et al.  Failure of peripheral arterial balloon angioplasty: does platelet deposition play a role?. Eur J Vasc Surg. 1991;5:541–547
  78. Miller DD, Rivera FJ, Garcia OJ, Palmaz JC, Berger HJ, Weisman HF. Imaging of vascular injury with 99m Tc-labelled monoclonal antiplatelet antibody S12. Preliminary experience in human percutaneous transluminal angioplasty. Circulation. 1992;85:1354–1363
  79. Rossi P, Kuukasjarvi P, Salenius JP, et al.  Percutaneous transluminal angioplasty increases thromboxane A2 production in claudicants. Prost Leuk & Ess Fatty Acids. 1997;56:369–372
  80. Nyamekye I, Costa D, Raphael M, Bishop CC. Thrombosis and restenosis after peripheral angioplasty: does acute 111-indium platelet accumulation predict angioplasty outcome?. Eur J Vasc Endovasc Surg. 1997;13:388–393
  81. Golino P, Ambrosio G, Ragni M, et al.  Inhibition of leucocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury. Thromb Haemost. 1997;77:783–788
  82. Heiss HW, Just H, Middleton D, Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology. 1990;41:263–269
  83. Hess H, Muller-Fassbender H, Ingrisch H, Mietaschk A. Prevention of re-occlusion after recanalisation of occluded arteries by the catheter method. Deutsche Medizinische Wochenschrift. 1978;103:1994–1997
  84. Parsson H, Norgren L, Ivancev K, Thorne J, Jonsson BA. Thrombogenicity of metallic vascular stents in arteries and veins–an experimental study in pigs. Eur J Vasc Surg. 1990;4:617–623
  85. Tarnok A, Mahnke A, Muller M, Zotz RJ. Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platetet activation and platelet-leukocyte aggregation. Cytometry. 1999;38:30–39
  86. Breckwoldt WL, Belkin M, Gould K, Allen M, Connolly RJ, Termin P. Modification of the thrombogenicity of a selfexpanding vascular stent. J Invest Surg. 1991;4:269–278
  87. Verheye S, Markou CP, Salame MY, et al.  Reduced thrombus formation by hyaluronic acid coating of endovascular devices. Arterioscler Thromb Vasc Biol. 2000;20:1168–1172
  88. Mueller MR, Salat A, Stangl P, et al.  Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78:1003–1007
  89. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. NEJM. 2001;345:494–502
  90. Kohler TR, Kaufman JL, Kacoyanis GP, et al.  Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery. 1984;96:462–466
  91. Donaldson DR, Salter MC, Kester RC, et al.  The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vasc Surg. 1985;19:224–230
  92. McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh RM. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg. 1991;13:150–162

PII: S1078-5884(03)70179-8

doi: 10.1053/ejvs.2002.1795

European Journal of Vascular & Endovascular Surgery
Volume 25, Issue 1 , Pages 6-15 , January 2003

Article Tools

* Image Usage & Resolution